Navigation Links
UC Irvine receives $2.18M to explore nano advancements in DNA sequencing
Date:10/1/2007

Irvine, Calif., Oct. 1, 2007 UC Irvines Henry Samueli School of Engineering has been awarded $2.18 million to blend traditional DNA sequencing techniques with cutting-edge nanotechnology to develop a faster and less costly method of analysis. The goal is to make DNA sequencing feasible as a routine part of health care.

If implemented, widespread DNA analysis could provide doctors with more resources to predict disease, prevent potential illness and better customize prescription medication to complement patients specific health and treatment needs.

UC Irvines three-year grant was awarded as part of a $15 million initiative by the National Human Genome Research Institute (NHGRI) to support the development of innovative technologies with the potential to drastically reduce the cost of DNA sequencing.

The institute, part of the National Institutes of Health (NIH), announced grants for eight researchers to develop genome sequencing technologies that could produce a total genetic composition of an individual for $1,000. UC Irvine received the second largest of these grants.

Three additional researchers were funded to work on nearer-term technologies that could sequence a genome for $100,000. Currently, it costs about $5 million to sequence DNA for humans and other mammals by painstakingly analyzing the 3 billion base pairs that comprise the building blocks of DNA. The process can take months to complete.

If we could make DNA sequencing and testing available for all patients during medical exams by taking a simple blood test, we could directly impact the future of health care and create opportunities to improve a patients quality of life, said H. Kumar Wickramasinghe, professor of electrical engineering and computer science and the Henry Samueli endowed chair, who is leading this research at UC Irvine.

Wickramasinghe will work with Robert K. Moyzis, a professor in UC Irvines Department of Biological Chemistry
'/>"/>

Contact: Jason Mednick
jmednick@uci.edu
949-824-5951
University of California - Irvine
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. DuPonts first biologically derived polymer receives global recognition
2. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
3. Research on antibiotics receives historical recognition
4. Anthrax test, developed by army and CDC, receives FDA approval
5. Research team receives $7.5 million to study cassava
6. Live Recombinant Adenovirus Vaccine Technique Explored
7. Chemical Engineer Kao Explores Antibiotic Synthesis With DNA Chips
8. Experiment station researchers to explore genome of disease-fighting fungus
9. Census of Marine Life explorers surprised by diversity, density of Arctic creatures
10. Drug discovery team to explore newly discovered deep-sea reefs
11. ‘Blue Brain?project explores thought at molecular level

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...eries from collapsing have been true life-savers. ...eeded -- once the arteries are strengthened, they ...ice but to leave them in place. , Prof. Meital Z...omedical Engineering has developed a new patent-pe...,re needed, then dissolves. , "Our new composite...
(Date:11/24/2009)...secrets of the earth,s history locked in its icy d...tle information on the environments that have been.... Now, a team of researchers from nine institution...$10 million dollars by the National Science Founda...rally. These scientists will drill through the Wes...
(Date:11/23/2009)...vidence that the "synergistic" effect of early-lif...on and indoor endotoxin causes more harm to develo... , Environmental health scientists at the Univer...hown that children exposed to both high levels of ...ing early life are six times more likely to experi...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A Milestone of Opportunity for VNUS Medical Technologies 48130 1A Milestone of Opportunity for VNUS Medical Technologies 48130 2A Milestone of Opportunity for VNUS Medical Technologies 48130 3Providence Health 26 Services Increases Revenue by 2435 Million Using Concuity ClearContracts 12502 1Providence Health 26 Services Increases Revenue by 2435 Million Using Concuity ClearContracts 12502 2Providence Health 26 Services Increases Revenue by 2435 Million Using Concuity ClearContracts 12502 3Forterus Inc Announces Free Outpatient Treatment to Military Veterans Back from War Zones 48129 1Forterus Inc Announces Free Outpatient Treatment to Military Veterans Back from War Zones 48129 2
...unisia, supported by the European Commission, high... health in countries bordering the Mediterranean S...rtance of Euro-Mediterranean partnerships in order...e sciences ?in particular following the mapping of...rove scientific knowledge and approaches to improv...
... radiotherapy, on a cellular scale. Antibodies cou..., bind to and kill cancerous cells. Provided that ...ce between normal and cancerous cells; this is not... for lymphoma that takes a fraction of the time of...caused tumors to shrink in 95 percent of patients,...
...called CD14 binds to substances liberated from the...nisms. In a report published in the Journal of Bio...heir elucidation of three-dimensional structure of...d to certain bacterial products. , The research ap...ssue of the Journal of Biological Chemistry, an Am...
Other Biology News:Measuring the impact of post-genomics on Mediterranean populations 2New Treatment Rivals Chemotherapy For Lymphoma, Study Finds 2New Treatment Rivals Chemotherapy For Lymphoma, Study Finds 3Scientists solve structure of key protein in innate immune response 2
(Date:11/24/2009)... Health care employment grew by 29,000 jobs in Oc...consistent growth during the U.S. recession. Howev...ble, and health systems are coming closer to havin...st administrators. , (Voc...ntinued growing in October despite the shedding of...
(Date:11/24/2009)...I, Nov. 24 /PRNewswire-Asia/ -- NOD Pharmaceutical...ice (PTO) has allowed the patent application for,i..., NOD technology is a highly efficient ap...o-adhesive nano-particles to enable oral delivery ... technology is a platform technology,that can be a...
(Date:11/24/2009)...HAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai Biolaxy...istration (SFDA) has approved the,investigational ...oject,(Nodlin), an innovative insulin formulation ...y to initiate its first phase I clinical study. ,...high blood glucose and poor,metabolism. The compli...
(Date:11/24/2009)...The FBI recently approved the Promega PowerPlex 16...n or generating DNA records for the National DNA I...I USA (PRWEB) -- The FBI recently approved the Pro...ratories participating in, or generating DNA recor... currently contains more than seven million profil...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2
... CITY, New Jersey, November 26, Rosetta Genomics (...third quarter financial results on December 5, 200...will host a conference call with a,simultaneous we...Friday,December 5. , To access the live conf...al 1-866-966-5335; international participants may ...
...E, Nov. 26 Spectrum,Pharmaceuticals, Inc. (Nasdaq...CTIC )(MTA: CTIC) announced today they have entere...nture, RIT Oncology LLC, to commercialize and,deve... United States.,ZEVALIN, a radioimmunotherapeutic ...by Cell Therapeutics, Inc. (CTI) for the treatment...
...Equels, President and Managing,Director of the Equ...ectors,for Hemispherx BioPharma, Inc. (Amex: HEB... engaged in the manufacture and clinical developme... and immune-based disorders. , Equels, legal...r emphasis,on civil racketeering, business torts a...
Other Biology Technology:Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results 2Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 2Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 3Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 4Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 5Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 6Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 7Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 8Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 3
Stirbar, Trans-Blot Plus cell from Bio-Rad
Super Cooling Coil, Trans-Blot cell from Bio-Rad
Criterion Staining and Blotting Trays, with lids, 12 from Bio-Rad
...ting a wide range of next-generation features into...andard for flexible laboratory solutions. It puts ...ng, dilution, dispensing, and integrations into a...exible as it is efficient and economical. The Biom...
Biology Products: